Gubra stock

GUBRA · Nasdaq Copenhagen · DKK

Compare Gubra
kr 265.00Change from previous close: −0.75%Absolute change: −kr 2.00

Close · November 20, 2026

Price history

−46.98% over the period

1 year: from kr 499.80 (November 20, 2025) to kr 265.00 (November 20, 2026), −46.98%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026kr 265.00
October 30, 2026kr 297.80
September 30, 2026kr 320.00
August 31, 2026kr 379.40
July 31, 2026kr 386.80
June 30, 2026kr 321.80
May 29, 2026kr 357.40
April 30, 2026kr 317.40
March 31, 2026kr 355.00
February 27, 2026kr 391.00
January 30, 2026kr 452.00
December 30, 2025kr 517.50
November 28, 2025kr 491.80
November 20, 2025kr 499.80

At a glance

  • The company

    Disease-agnostic techbio company offering peptide-based drug discovery and preclinical contract research services across metabolic and fibrotic diseases

  • Latest results

    Quarter to September 30, 2026

TickerLandia's take on Gubra

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 272.00
52-wk highkr 557.50

−52.47% from the 52-week high

Analysts · 3 analysts

Average targetkr 515.00+94.34% vs. price

Buy 2 · Hold 1 · Sell 0 · Buy

TickerLandia Fingerprint: Gubra

Compared with similar companies: very weak momentum and very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Gubra is pricier than similar companies

Gubra's Forward P/E: 173.8, +232% against the median of a group of 6 similar companies (52.3).

Compared with 6 similar companies

Gubra's metrics compared with similar companies
MetricGubraPosition in the groupBand
Forward P/E173.8High
Operating margin-73.1%Low
ROE-16.1%Low
Debt/equity0.18Middle
Price/book4.75Middle

Grey band: the middle half of the group; tick: the median; dot: Gubra. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 126.35M

Latest quarter · Q2 2026

Net income

-kr 109.96M

Latest quarter · Q2 2026

Quarterly net margin

-87.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 4.97B
EPS
-kr 11.10
Volume
36.92K
Daily trading
€3.19M

How Gubra is changing

All results
  • Revenue grew 72.6% a year on average over the last 5 years

  • Operating margin rose from −14.8% to 81.5%

  • Profits turn into cash: free cash flow equal to 101% of net income

Returns

Gubra returns with dividends

kr 1,000 invested in Gubra 3 years ago, on November 20, 2023, would be worth kr 2,231 today: +123.06% in total, +30.65% per year. This is the price return only: dividends are excluded.

PeriodGubrakr 1,000 becomes
1 month−13.06%kr 869
6 months−22.24%kr 778
Year to date−48.79%kr 512
1 year−46.98%kr 530
3 years+123.06%kr 2,231

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Gubra: technical analysis

Gubra is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 63.6% below its all-time closing high (kr 728.00, December 18, 2024).

Trend
Downward
RSI (14 sessions)
35
Between 30 and 70
vs 200-session average
−22.43%

Active signals

  • New 52-week low.

    since November 18, 2026

Support and resistance

Price areas where Gubra has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 315.74+19.15%7 touches, last on November 9, 2026
  2. Resistancekr 291.60+10.04%2 touches, last on September 16, 2026
  3. Resistancekr 281.50+6.23%2 touches, last on November 10, 2026
  4. Last pricekr 265.00
  5. No support below: the price is near the lows of the year

Volatility and risk

Volatility (60 sessions, annualised)
53.3%
Largest fall in the last year
−50.37%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

Gubra and its competitors

Based in Horsholm, Denmark, and founded in 2008, Gubra works in peptide-based drug discovery and preclinical contract research. Its contract research and development services cover metabolic and fibrotic diseases and are offered to pharmaceutical and biotechnology companies in Europe, North America and other international markets. The services include in vivo pharmacology, biomarker assays, bioinformatics, next generation sequencing and histology with artificial intelligence pathology.

Headquarters
Horsholm, Denmark
Employees
330
Founded
2008
Chief executive
Markus Rohrwild
Gubra and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
GubraGUBRA$730.02M-73.1%—−22.24%
DBV TechnologiesDBV$572.52M-5,577.0%—−48.73%
Pharming GroupPHARM$841.25M12.8%36.1−2.57%
InventivaIVA$890.8M-5,980.9%—−33.75%
PhilogenPHIL$905.96M79.1%3.67−5.63%
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+35.06%

Same industry or related industries, similar size. Compare Gubra with its competitors · Full profile